SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.1267 per share and revenue of $8.10 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 7:00 AM ET.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Wednesday, March 4th. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.04). SCYNEXIS had a negative net margin of 41.79% and a negative return on equity of 25.52%. The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $8.10 million.

SCYNEXIS Stock Up 2.8%

Shares of SCYNEXIS stock opened at $0.90 on Wednesday. SCYNEXIS has a 52-week low of $0.57 and a 52-week high of $1.31. The company has a market capitalization of $40.19 million, a P/E ratio of -5.29 and a beta of 1.33. The company has a 50 day moving average of $0.78 and a 200 day moving average of $0.76.

Hedge Funds Weigh In On SCYNEXIS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SCYX. Jane Street Group LLC purchased a new position in SCYNEXIS in the second quarter valued at approximately $27,000. Bridgeway Capital Management LLC lifted its position in shares of SCYNEXIS by 4.2% during the 2nd quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after buying an additional 14,689 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of SCYNEXIS by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock valued at $284,000 after buying an additional 29,775 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of SCYNEXIS in the 4th quarter valued at $1,255,000. Finally, Vanguard Group Inc. grew its position in shares of SCYNEXIS by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock valued at $1,357,000 after buying an additional 105,600 shares during the last quarter. 54.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a report on Monday, December 29th. Wall Street Zen downgraded shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Monday. Finally, reissued a “buy” rating on shares of SCYNEXIS in a report on Monday, March 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

About SCYNEXIS

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.